Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | WIZ | O95785 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24269093 | 0.90 | CRBN (0.51) | CRBNDDB1ARMAOBALB | |
| SCHEMBL24269441 | 0.88 | DDB1 (0.51) | CRBNDDB1PIK3CAPRKDC | |
| SCHEMBL22502565 | 0.85 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL31601585 | 0.85 | CRBN (0.52) | CRBNDDB1 | |
| SCHEMBL30938959 | 0.85 | DDB1 (0.55) | CRBNDDB1 | |
| SCHEMBL22502648 | 0.82 | DDB1 (0.57) | CRBNDDB1MAOB | |
| SCHEMBL27265870 | 0.82 | DDB1 (0.53) | CRBNDDB1PIK3CAPRKDC | |
| SCHEMBL30919790 | 0.82 | DDB1 (0.53) | CRBNDDB1PIK3CAPRKDC | |
| SCHEMBL26699653 | 0.82 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL31334185 | 0.81 | DDB1 (0.46) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | CRBN 91/4885DDB1 33/4885AR 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.